nach oben

27.03.2019 | Original Article

Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis

verfasst von: Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Jun Yuan, Yuefang Jiang

Einloggen, um Zugang zu erhalten

Abstract

Background

Numerous recent studies have shown that concomitant carcinoma in situ (CIS) can be closely associated with the prognosis of patients with bladder cancer (BCa). However, the prognostic value of CIS in BCa is still not conclusive. Hence, we performed a systematic review and meta-analysis to explore the association between CIS and clinicopathological features and the prognostic value for BCa following radical cystectomy.

Methods

We performed this study in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Relevant studies were systematically collected from PubMed, EMBASE, and Web of Science, with an expiration date of August 2018. Hazard ratios and 95% confidence intervals (CIs) were pooled to assess the intensity of association. All data were analyzed by Stata 12.0. Moreover, heterogeneity and publication bias were determined, and sensitivity analysis was performed to examine whether the findings of the meta-analysis were robust.

Results

A total of 18,845 patients from 24 studies were included in the analysis. Our results indicated that CIS has no significant correlation with cancer-specific mortality (CSM) (pooled HR = 0.97, 95% CI 0.93–1.00, p = 0.059), overall mortality (OM) (pooled HR = 0.93, 95% CI 0.85–1.01, p = 0.076), overall survival (OS) (pooled HR = 1.04, 95% CI 0.96–1.12, p = 0.386), cancer-specific survival (CSS) (pooled HR = 1.06, 95% CI 0.97–1.16, p = 0.186), recurrence-free survival (RFS) (HR = 1.05, 95% CI 0.99–1.11, p = 0.098) or recurrence (pooled HR = 1.04, 95% CI 0.98–1.11, p = 0.212) in BCa patients. In addition, CIS was not correlated with gender (male vs. female, OR = 1.00, 95% CI 0.74–1.34, p = 0.978), pathological stage (III/IV vs. I/II: OR = 0.74, 95% CI 0.50–1.10, p = 0.132), tumor grade (1/2 vs. 3: OR = 3.38, 95% CI 0.73–15.65, p = 0.119), soft tissue surgical margin (STSM) (+ vs. − : OR = 1.20, 95% CI 0.97–1.48, p = 0.093) or lymphovascular invasion (LVI) (+ vs. − : OR = 0.92, 95% CI 0.62–1.38, p = 0.702),but was closely related to adjuvant chemotherapy (ACT) (yes vs. no, OR = 1.17, 95% CI 1.03–1.32, p = 0.019). Furthermore, these findings were demonstrated to be reliable by our sensitivity and subgroup analysis.

Conclusions

The prognostic value of CIS in BCa remains inconclusive in patients submitted to RC. Our data indicated that CIS may have no significant correlation with the prognosis and clinicopathological parameters of BCa patients, and also may not be applied to risk stratification or individualized therapy in BCa patients. Further research should be conducted to confirm our findings.

Nur mit Berechtigung zugänglich

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. https://doi.org/10.1002/ijc.29210 CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA 67(1):7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM, Hernandez V, Espinos EL, Dunn J, Rouanne M, Neuzillet Y, Veskimae E, van der Heijden AG, Gakis G, Ribal MJ (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71(3):462–475. https://doi.org/10.1016/j.eururo.2016.06.020 CrossRefPubMed

Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M (2013) Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 37(3):219–225. https://doi.org/10.1016/j.canep.2013.02.002 CrossRefPubMed

Ploussard G, Shariat SF, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, Rieken M, Rink M, Matsumoto K, Kikuchi E, Klatte T, Boorjian SA, Lotan Y, Roghmann F, Fairey AS, Fradet Y, Black PC, Rendon R, Izawa J, Kassouf W (2014) Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. Eur Urol 66(2):361–370. https://doi.org/10.1016/j.eururo.2013.09.050 CrossRefPubMed

Rodriguez Faba O, Palou J, Rosales A, Breda A, Algaba F, Urdaneta G, Villavicencio H (2011) Clinical predictive factors of poor outcome in patients with stage pT0 disease at radical cystectomy. J Urol 186(2):442–447. https://doi.org/10.1016/j.juro.2011.03.134 CrossRefPubMed

Antunes AA, Nesrallah LJ, Dall’Oglio MF, Ferreira YA, Passerotti CC, Leite KR, Ortiz V, Srougi M (2006) Analysis of prognostic factors in patients with transitional cell carcinoma of the bladder treated with radical cystectomy. Int Braz J Urol 32(1):35–42CrossRef

Muppa P, Gupta S, Frank I, Boorjian SA, Karnes RJ, Thompson RH, Thapa P, Tarrell RF, Herrera Hernandez LP, Jimenez RE, Cheville JC (2017) Prognostic significance of lymphatic, vascular and perineural invasion for bladder cancer patients treated by radical cystectomy. Pathology 49(3):259–266. https://doi.org/10.1016/j.pathol.2016.12.347 CrossRefPubMed

Dotan ZA, Kavanagh K, Yossepowitch O, Kaag M, Olgac S, Donat M, Herr HW (2007) Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol 178(6):2308–2313. https://doi.org/10.1016/j.juro.2007.08.023 CrossRefPubMed

10.

Moschini M, Shariat SF, Abufaraj M, Soria F, Klatte T, Croce G, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A (2017) The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. Urol Oncol 35(4):151 e117–151 e123. https://doi.org/10.1016/j.urolonc.2016.11.003 CrossRef

11.

Barth I, Schneider U, Grimm T, Karl A, Horst D, Gaisa NT, Knuchel R, Garczyk S (2018) Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. Virchows Archiv 472(5):749–758. https://doi.org/10.1007/s00428-018-2354-9 CrossRefPubMedPubMedCentral

12.

Gupta A, Lotan Y, Bastian PJ, Palapattu GS, Karakiewicz PI, Raj GV, Schoenberg MP, Lerner SP, Sagalowsky AI, Shariat SF, Bladder Cancer Research C (2008) Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 71(2):302–307. https://doi.org/10.1016/j.urology.2007.10.041 CrossRefPubMed

13.

Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Saad F, Bell D, Drachenberg D, Kassouf W (2014) Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World J Urol 32(5):1295–1301. https://doi.org/10.1007/s00345-013-1207-z CrossRefPubMed

14.

Nuhn P, Bastian PJ, Novara G, Svatek RS, Karakiewicz PI, Skinner E, Fradet Y, Izawa JI, Kassouf W, Montorsi F, Müller SC, Fritsche H-M, Sonpavde G, Tilki D, Isbarn H, Ficarra V, Dinney CP, Shariat SF (2011) Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. Urol Int 87(1):42–48. https://doi.org/10.1159/000325463 CrossRefPubMed

15.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1–e34. https://doi.org/10.1016/j.jclinepi.2009.06.006 CrossRef

16.

Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-z CrossRefPubMed

17.

Li Z, Wang K-E, Zhou X-L, Zhou J, Ye C-H (2018) Long non-coding RNA cancer susceptibility candidate 2a (CASC2a) is a marker of early recurrence after radical cystectomy in patients with urothelial carcinoma of the bladder. Med Sci Monit 24:438–447. https://doi.org/10.12659/msm.905393 CrossRefPubMedPubMedCentral

18.

Kang M, Balpukov UJ, Jeong CW, Kwak C, Kim HH, Ku JH (2017) Can the preoperative neutrophil-to-lymphocyte ratio significantly predict the conditional survival probability in muscle-invasive bladder cancer patients undergoing radical cystectomy? Clin Genitourin Cancer 15:e411–e420. https://doi.org/10.1016/j.clgc.2016.10.015 CrossRefPubMed

19.

Vallo S, Gilfrich C, Burger M, Volkmer B, Boehm K, Rink M, Chun FK, Roghmann F, Novotny V, Mani J, Brisuda A, Mayr R, Stredele R, Noldus J, Schnabel M, May M, Fritsche HM, Pycha A, Martini T, Wirth M, Roigas J, Bastian PJ, Nuhn P, Dahlem R, Haferkamp A, Fisch M, Aziz A (2016) Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder. Urol Oncol 34(10):432 e431–432 e438. https://doi.org/10.1016/j.urolonc.2016.05.008 CrossRef

20.

Nguyen DP, Al Hussein Al Awamlh B, O’Malley P, Khan F, Lewicki PJE, Golombos DM, Scherr DS (2016) Factors impacting the occurrence of local, distant and atypical recurrences after robot-assisted radical cystectomy: a detailed analysis of 310 patients. J Urol 196(5):1390–1396. https://doi.org/10.1016/j.juro.2016.05.101 CrossRefPubMed

21.

Soave A, John LM, Dahlem R, Minner S, Engel O, Schmidt S, Kluth LA, Fisch M, Rink M (2015) The impact of tumor diameter and tumor necrosis on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. Urology 86(1):92–98. https://doi.org/10.1016/j.urology.2015.03.036 CrossRefPubMed

22.

Parker WP, Ho PL, Melquist JJ, Scott K, Holzbeierlein JM, Lopez-Corona E, Kamat AM, Lee EK (2015) The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival. J Urol 193(5):1494–1499. https://doi.org/10.1016/j.juro.2014.11.003 CrossRefPubMed

23.

Kwon T, Jeong IG, Lee J, Lee C, You D, Hong B, Hong JH, Ahn H, Kim CS (2015) Adjuvant chemotherapy after radical cystectomy for bladder cancer: a comparative study using inverse-probability-of-treatment weighting. J Cancer Res Clin Oncol 141(1):169–176. https://doi.org/10.1007/s00432-014-1793-1 CrossRefPubMed

24.

Gaisa NT, Wilms H, Wild PJ, Jakse G, Heidenreich A, Knuechel R (2015) In cystectomy specimens with bladder cancer whole organ embedding increases the detection rate of histopathological parameters, but not of those with prognostic significance. Virchows Arch 466(4):423–432. https://doi.org/10.1007/s00428-015-1726-7 CrossRefPubMed

25.

Ferro M, De Cobelli O, Buonerba C, Di Lorenzo G, Capece M, Bruzzese D, Autorino R, Bottero D, Cioffi A, Matei DV, Caraglia M, Borghesi M, De Berardinis E, Busetto GM, Giovannone R, Lucarelli G, Ditonno P, Perdona S, Bove P, Castaldo L, Hurle R, Musi G, Brescia A, Olivieri M, Cimmino A, Altieri V, Damiano R, Cantiello F, Serretta V, De Placido S, Mirone V, Sonpavde G, Terracciano D (2015) Modified glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical cystectomy: a multicenter experience. Medicine 94(42):e1861. https://doi.org/10.1097/MD.0000000000001861 CrossRefPubMedPubMedCentral

26.

May M, Brookman-May S, Burger M, Gilfrich C, Fritsche HM, Rink M, Chun F, Fisch M, Roghmann F, Noldus J, Mayr R, Pycha A, Novotny V, Wirth M, Vallo S, Haferkamp A, Roigas J, Brisuda A, Stredele R, Volkmer B, Dechet C, Schnabel M, Denzinger S, Stief CG, Bastian PJ, Aziz A (2014) Concomitant seminal vesicle invasion in pT4a urothelial carcinoma of the bladder with contiguous prostatic infiltration is an adverse prognosticator for cancer-specific survival after radical cystectomy. Ann Surg Oncol 21(12):4034–4040. https://doi.org/10.1245/s10434-014-3827-y CrossRefPubMed

27.

Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, Lotan Y, Kassouf W, Fritsche H-M, Pycha A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, Scherr DS, Shariat SF (2013) Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. BJU Int 111(1):74–84. https://doi.org/10.1111/j.1464-410X.2012.11356.x CrossRefPubMed

28.

Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y, Bolenz C, Margulis V, Raj GV, Sagalowsky AI, Shariat SF (2013) Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol 64(3):465–471. https://doi.org/10.1016/j.eururo.2013.03.043 CrossRefPubMed

29.

da Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, Guglielmetti GB, Pycha A, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Zerbib M, Scherr DS, Shariat SF (2013) Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol 190(2):487–492. https://doi.org/10.1016/j.juro.2013.02.003 CrossRefPubMed

30.

Otto W, May M, Fritsche HM, Dragun D, Aziz A, Gierth M, Trojan L, Herrmann E, Moritz R, Ellinger J, Tilki D, Buchner A, Hofner T, Brookman-May S, Nuhn P, Gilfrich C, Roigas J, Zacharias M, Denzinger S, Hohenfellner M, Haferkamp A, Muller SC, Kocot A, Riedmiller H, Wieland WF, Stief CG, Bastian PJ, Burger M (2012) Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder. Gend Med 9(6):481–489. https://doi.org/10.1016/j.genm.2012.11.001 CrossRefPubMed

31.

Denzinger S, Burger M, Fritsche H-M, Bertz S, Hofstädter F, Wieland WF, Hartmann A, Otto W (2009) Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder. Scand J Urol Nephrol 43(4):282–287. https://doi.org/10.1080/00365590902854354 CrossRefPubMed

32.

Muramaki M, Miyake H, Kurahashi T, Takenaka A, Inoue T-A, Fujisawa M (2008) Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer. Int J Urol 15(4):314–318. https://doi.org/10.1111/j.1442-2042.2008.02000.x CrossRefPubMed

33.

Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y (2007) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51(1):152–160. https://doi.org/10.1016/j.eururo.2006.08.037 CrossRefPubMed

34.

Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF (2007) Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8(2):128–136. https://doi.org/10.1016/s1470-2045(07)70002-5 CrossRefPubMed

35.

Miao C, Liang C, Zhu J, Xu A, Zhao K, Hua Y, Zhang J, Chen W, Suo C, Zhang C, Liu Y, Su S, Wang Z (2017) Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis. Oncotarget 8(19):32309–32321. https://doi.org/10.18632/oncotarget.15907 CrossRefPubMedPubMedCentral

36.

Booth CM, Siemens DR, Wei X, Peng Y, Berman DM, Mackillop WJ (2015) Pathological factors associated with survival benefit from adjuvant chemotherapy (ACT): a population-based study of bladder cancer. BJU Int 116(3):373–381. https://doi.org/10.1111/bju.12913 CrossRefPubMed

37.

Aziz A, Shariat SF, Roghmann F, Brookman-May S, Stief CG, Rink M, Chun FK, Fisch M, Novotny V, Froehner M, Wirth MP, Schnabel MJ, Fritsche HM, Burger M, Pycha A, Brisuda A, Babjuk M, Vallo S, Haferkamp A, Roigas J, Noldus J, Stredele R, Volkmer B, Bastian PJ, Xylinas E, May M (2016) Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making. BJU Int 117(2):272–279. https://doi.org/10.1111/bju.12984 CrossRefPubMed

38.

Wheat JC, Weizer AZ, Wolf JS Jr, Lotan Y, Remzi M, Margulis V, Wood CG, Montorsi F, Roscigno M, Kikuchi E, Zigeuner R, Langner C, Bolenz C, Koppie TM, Raman JD, Fernandez M, Karakiewizc P, Capitanio U, Bensalah K, Patard JJ, Shariat SF (2012) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol Oncol 30(3):252–258. https://doi.org/10.1016/j.urolonc.2010.01.001 CrossRefPubMed

39.

Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larre S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmstrom PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J (2015) Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients. Eur Urol 67(1):74–82. https://doi.org/10.1016/j.eururo.2014.06.040 CrossRefPubMed

40.

Masood S, Sriprasad S, Palmer JH, Mufti GR (2004) T1G3 bladder cancer-indications for early cystectomy. Int Urol Nephrol 36(1):41–44CrossRef

41.

Laurent M, Brureau L, Demery ME, Flechon A, Thuaut AL, Carvahlo-Verlinde M, Bastuji-Garin S, Paillaud E, Canoui-Poitrine F, Culine S (2017) Early chemotherapy discontinuation and mortality in older patients with metastatic bladder cancer: the AGEVIM multicenter cohort study. Urol Oncol 35(1):34.e39. https://doi.org/10.1016/j.urolonc.2016.08.003 CrossRef

42.

Ye Z, Chen J, Hong Y, Xin W, Yang S, Rao Y (2018) The efficacy and safety of intravesical gemcitabine vs Bacille Calmette–Guerin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis. OncoTargets Ther 11:4641–4649. https://doi.org/10.2147/OTT.S170477 CrossRef

Titel: Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis
verfasst von: Lijin Zhang
Bin Wu
Zhenlei Zha
Hu Zhao
Jun Yuan
Yuefang Jiang
Publikationsdatum: 27.03.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02738-2

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Urologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Darf man die Behandlung eines Neonazis ablehnen?

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Urologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Urologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Darf man die Behandlung eines Neonazis ablehnen?

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Urologie